中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Fat Metabolism in OSA and COPD

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态主动,不招募
赞助商
Texas A&M University

关键词

抽象

Obstructive sleep apnea (OSA) is the most common type of sleep apnea and is caused by an obstruction of the upper airways. The obstruction results in periods of intermittent hypoxia and re-oxygenation, which lead to increased oxidative stress, increased inflammation, endothelial dysfunction, and insulin resistance. Chronic obstructive pulmonary disease (COPD) is a lung disease that leads to poor airflow. This disease leads to systemic hypoxia, reduced oxidative capacity, and increased inflammation. The direct cause of OSA and COPD is unclear, but OSA and COPD may be linked to other comorbid conditions such as obesity and type II diabetes. Upon onset of OSA and COPD, metabolic disturbances associated with obesity and type II diabetes can be exacerbated.
Obesity is a condition characterized by an increase in visceral fat, elevated plasma levels of free fatty acids, inflammation, and insulin resistance. Although the effects of body fat distribution have not been studied in these patients, an increase in both subcutaneous and abdominal fat mass in non-OSA older women was shown to increase morbidity and mortality. Fat/adipose tissue is an active tissue capable of secreting proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, reactive oxygen species and adipokines. Particularly, abdominal fat is a prominent source of pro-inflammatory cytokines, which contributes to a low grade, chronic inflammatory state in these patients. Additionally, an increased inflammatory state is associated with reduced lean body mass, and together with elevated circulating free fatty acids may increase the occurrence of lipotoxicity and insulin resistance. Thus, increased fat deposition is associated with a poor prognosis in OSA and COPD patients and therefore it is of clinical and scientific importance to understand the changes in fat metabolism and digestion as a result of OSA and COPD.
It is therefore our hypothesis that fat synthesis and insulin resistance is increased and whole body protein synthesis is decreased in OSA and COPD patients, leading to a poor prognosis.

描述

This research study involves 3 visits for subjects and healthy controls. The first visit is the screening visit and includes review of the informed consent and a DXA scan and the second and third visit for the study days. For the first test day, 3 hours of the subjects time will be for urine and blood sample collection, and to stable isotope administration (deuterated water, isotopically labeled amino acids). Subjects are allowed to go home after and eat normally. On the second study day, subjects will arrive early that morning. For the duration of the study, subjects have to lie in the bed (except for bathroom privileges). They can watch tv or bring and use a book/tablet. The research nurse or study staff will be present in the human subject area to assist the subject if necessary. Subjects are not allowed to eat or drink during the second test day, except for the test drink (meal) and water. One IV catheter will be placed in a vein of the arm/hand for blood draws. The hand will be placed in a hot box during blood collection. Another IV catheter will be placed in the contra-lateral forearm for a primed and continuous infusion of isotopes (isotopically labeled amino acids and glycerol). Each day, a total of 80-100 ml of blood will be obtained. Stable isotopes will be ingested and infused on the first test day and added to the test drinks and infused on the second day. On the second test day, subjects will fill out questionnaires. After completion of the study, we will provide the subject with a meal.

日期

最后验证: 05/31/2020
首次提交: 06/03/2014
提交的预估入学人数: 06/03/2014
首次发布: 06/05/2014
上次提交的更新: 06/21/2020
最近更新发布: 06/23/2020
实际学习开始日期: 03/31/2014
预计主要完成日期: 11/30/2017
预计完成日期: 01/31/2022

状况或疾病

Obstructive Sleep Apnea
Chronic Obstructive Pulmonary Disease
Obesity

-

手臂组

干预/治疗
COPD and OSA
Subjects with diagnosis of COPD and OSA
COPD
Subjects with diagnosis of COPD
OSA
Subjects with diagnosis of OSA
controls
Gender, age, BMI matched controls

资格标准

有资格学习的年龄 30 Years 至 30 Years
有资格学习的性别All
取样方式Probability Sample
接受健康志愿者
标准

Inclusion criteria subjects:

- Established diagnosis of OSA or COPD

- Ability to sign informed consent

- Ability to walk, sit down and stand up independently

- Age 30 years and older

- Ability to lie in supine position for up to 8 hours

- Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease

- Willingness and ability to comply with the protocol

Inclusion criteria healthy normal weight and obese subjects:

- Healthy male & female according to the investigator's or appointed staff's judgment

- Ability to walk, sit down and stand up independently

- Age 30 years or older

- Ability to lay in supine or elevated position for 8 hours

- No diagnosis of OSA or COPD

- Willingness and ability to comply with the protocol

Exclusion Criteria

- Established diagnosis of malignancy

- Untreated metabolic diseases including hepatic or renal disorder

- Presence of acute illness or metabolically unstable chronic illness

- Presence of fever within the last 3 days

- Any other condition according to the PI or study physician that would interfere with proper conduct of the study / safety of the patient

- Use of long-term oral corticosteroids or short course of oral corticosteroids in the preceding month before enrollment

- Use of protein or amino acid containing nutritional supplements within 5 days of first study day 5 days of first study day

- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements

- History of hypo- or hyper-coagulation disorders, including use of a Coumadin derivative, history of deep venous thrombosis (DVT), or pulmonary embolism (PE) at any point in lifetime

- Currently taking anti-thrombotics and cannot stop for 7 days (i.e. medical indication)

- Recent myocardial infarction ( < 1 year ago)

- Current alcohol or drug abuse

- (Possible) pregnancy

结果

主要结果指标

1. Hepatic triglyceride synthesis [Pre meal ingestion and 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, and 300 min post meal ingestion]

changes in hepatic triglyceride synthesis before and after a meal

2. Hepatic de novo lipogenesis [Pre meal ingestion and 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, and 300 min post meal ingestion]

changes in hepatic de novo lipogenesis before and after a meal

3. Adipose tissue triglyceride synthesis [pre and 4 hours post meal]

changes in adipose tissue triglyceride synthesis before and after a meal

4. Adipose tissue de novo lipogenesis [pre and 4 hours post meal]

changes in adipose tissue de novo lipogenesis before and after a meal

5. Adipose tissue lipolysis - glycerol rate of appearance [Pre meal ingestion and 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, and 300 min post meal ingestion]

changes in adipose tissue lipolysis before and after a meal. plasma enrichment of glycerol.

6. Rate of appearance of ingested glucose [Pre meal ingestion and 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, and 300 min post meal ingestion]

determine changes in appearance of glucose rate in subjects

7. Endogenous Glucose Production [Pre meal ingestion and 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, and 300 min post meal ingestion]

Determine whole body glucose production in subjects

8. Glucose disposal [Pre meal ingestion and 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, and 300 min post meal ingestion]

Determine whole body glucose uptake in subjects

9. Net whole-body protein synthesis [0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210 min post-meal]

change in whole-body protein synthesis rate after intake of meal

10. Citrulline Rate of appearance [Postabsorptive state during 2 hours]

plasma enrichment of citrulline

11. Arginine turnover rate [postabsorptive state during 3 hours]

Arginine enrichment in plasma

12. Whole body collagen breakdown rate [Postabsorptive state during 3 hours]

Hydroxyproline enrichment in plasma

13. Tryptophan turnover rate [Postabsorptive state during 3 hours]

Tryptophan enrichment in plasma

14. Myofibrillar protein breakdown rate [0,15,30,45,60,75,90,105,120,150,180,210 min post-meal]

3methylhistidine enrichment in plasma

15. Glycine rate of appearance [Postabsorptive state during 3 hours]

glycine enrichment in plasma

16. Taurine turnover rate [postabsorptive state during 3 hours]

enrichment of taurine in

次要成果指标

1. Fat digestion and absorption [Pre meal ingestion and 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, and 300 min post meal ingestion]

defining fat digestion and absorption after a meal. Enrichment in palmitic acid and tripalmitin fatty acids in plasma

2. Insulin response to feeding [pre and up to 5 hours post meal]

acute changes from postabsorptive state to postprandial state

3. Body composition [1 day]

body composition will be determined by dual-energy X-ray absorptiometry and by deuterated water dilution technique. Plasma deuterium enrichments will be determined.

4. Physical activity questionnaire [1 day]

Outcome of physical activity assessment in breast cancer patients and healthy controls in relation to the fat metabolism

5. Protein digestion after feeding [0,15,30,45,60,75,90,105,120,150,180,210, min post-meal]

Ratio enrichment free phenylalanine vs phenylalanine from protein spirulina

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge